Development of a high performance liquid chromatography method for simultaneous analysis of theophylline, guaifenesin and diphenhydramine in an elixir
Purpose: To develop and validate a new low-cost high performance liquid chromatography (HPLC) method for simultaneous analysis of theophylline (TH), guaifenesin (GF) and diphenhydramine hydrochloride (DH) in elixir dosage form.
Methods: Chromatographic conditions were an isocratic elution with C18-Kromasil® column (250 x 4.6 mm, 5 μm), methanol-water (1:1, v/v, pH 3,0) as mobile phase, flow rate 1.0 ml/min and UV detector at λ 218 nm. The method was validated for selectivity, linearity, LOD-LOQ, precision, and accuracy.
Results: Retention time of TH, GF and DH was 3.3, 5.3 and 9.1 min, respectively. The method showed good selectivity, calibration curves were linear over the concentration range of 1.000 – 10.002 μg/mL, 0.801 – 8.008 μg/mL, and 0.251 – 2.514 μg/mL (r2 > 0.999). LOD was 0.1093, 0.16520, and 0.0706 μg/mL, while LOQ was 0.3645, 0.5506, and 0.2354 μg/mL for TH, GF and DH, respectively. Recovery accuracy was 99.77 - 101.10, 100.50 - 101.95 and 99.20 - 100.13 % for TH, GF and DH, respectively; precision (RSD) was < 2.0.
Conclusion: The proposed method is highly selective, sensitive, precise, and accurate, and would suitable for the simultaneous analysis of TH, GF, and DH in elixir dosage form. Since methanol is cheaper than acetonitrile, the application of the method may reduce the cost of analysis.
Keywords: Simultaneous analysis, Theophylline, Guaifenesin, Diphenhydramine hydrochloride, Elixir
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.